<DOC>
	<DOC>NCT00366119</DOC>
	<brief_summary>The purpose of this study is to assess which drug is more effective of Ramiprin®(ramipril) and Tritace®(ramipril) in the Treatment of Essential Hypertension</brief_summary>
	<brief_title>Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<criteria>mild and moderate essential hypertension (90mmHg≤DBP≤110mmHg) 180mmHg≤SBP If differences greater than 20mmHg for SBP and 10mmHg for DBP between both arms are present on 3 consecutive readings If differences greater than 20mmHg for SBP and 10mmHg for DBP are present on 3 consecutive readings impaired hepatic function imapaired renal function angioedema aortic valvular stenosis or obstrcutive ejection disorder primary hyperaldosteronism renal transplantation, bilateral renal artery stenosis or unilateral stenosis in a single kidney, hemodialysis severe respiratory disease congestive heart failure( New York Association functional class Ⅲ or Ⅳ) malignant hypertension labile angina pectoris or myocardial infarction in the last 3 months before study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>hypertension</keyword>
	<keyword>ramipril</keyword>
	<keyword>blood pressure</keyword>
	<keyword>artery stiffness</keyword>
	<keyword>BNP</keyword>
	<keyword>CRP</keyword>
</DOC>